BMC Pharmacology



Oral presentation Open Access

A molecular view of the regulation of sGC activity

Michael A Marletta*^{1,2}, Emily R Derbyshire², W Kaya Erbil¹, Nathaniel B Fernhoff², John Kuriyan^{1,2}, Charles Olea Jr², Mark S Price² and David E Wemmer¹

Address: ¹Department of Chemistry, University of California, Berkeley, California 94720-3220, USA and ²Department of Molecular and Cell Biology, University of California, Berkeley, California 94720-3220, USA

Email: Michael A Marletta* - marletta@berkeley.edu

from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications Regensburg, Germany. 19–21 June 2009

Published: 11 August 2009

BMC Pharmacology 2009, 9(Suppl 1):S27 doi:10.1186/1471-2210-9-S1-S27

This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/S27

© 2009 Marletta et al; licensee BioMed Central Ltd.

Mammalian sGC is a heterodimer composed of α - and β subunits (Figure 1). The C-terminus of each subunit contains a catalytic domain and the active site is composed of residues from both subunits. The catalytic domains also form a pseudosymmetric active site that contains residues known to be involved in nucleotide binding, but lack the amino acids required for catalysis. Sequence analysis shows that each subunit also contains well-defined PASlike domain, and a predicted helical region. The N-termini of the α - and β -subunits are homologous to the H-NOX (Heme-Nitric oxide/OXygen) family of proteins. The Nterminus of β-subunit contains a ferrous heme cofactor that serves a receptor for NO. sGC activity is also modulated by ATP and the substrate GTP and recent studies point toward a more complicated role for NO in the regulation of activity. Structural results coupled with biochemical and cellular experiments have broadened the current molecular view of the regulation of sGC.




Figure I Domain structure of sGC.

^{*} Corresponding author